No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
US OptionsDetailed Quotes
NVAX250110C8500
- 2.30
- +1.01+78.29%
15min DelayClose Jan 7 16:00 ET
2.85High2.26Low
2.40Open1.29Pre Close42 Volume474 Open Interest8.50Strike Price11.14KTurnover0.00%IV-0.18%PremiumJan 10, 2025Expiry Date2.32Intrinsic Value100Multiplier3DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma5.27Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Intraday
- 5D
- Daily
News
Options Alert: Why Novavax (NVAX) Could Be the Biotech Hero of Trump 2.0
US Records First Human Bird Flu Death, High Levels Of Respiratory Illnesses: Vaccine Stocks Rally
Moderna, Novavax and Other Vaccine Names Extend Gains Amid COVID/flu Concerns
Moderna Stock Jumps Amid Bird Flu Vaccine Hope After First U.S. Death -- Barrons.com
Why Novavax (NVAX) Stock Is Rising
Shares of Vaccine Makers Are Trading Higher After the First Bird Flu Death Was Reporting in the US. Additionally, a Recent DCD Report Noted an Increase in Acute Respiratory Illness Activity.